---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204147"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:55:47.472401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B

## Summary
- Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.
- CASGEVY revenue of $43M; collaboration expense net $45.9M, down on higher revenue share.
- Cash, equivalents and securities $2,441.8M, up from $1,975.8M, boosted by $585.4M convertible note.
- Zugo-cel started 3rd Phase 1 in autoimmune neurology; SLE patients remain in DORIS remission at Month 12 and Month 6.
- In vivo CTX310 IND cleared for US; CTX460 (AATD) and CTX340 (hypertension) on track for mid-2026 and H1 2026 clinical starts.

## SEC filing metadata
- accession: 0001193125-26-204147
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/0001193125-26-204147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/crsp-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204147
- JSON: https://secwatch.observer/filing/0001193125-26-204147.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204147.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported first quarter 2026 results: revenue $43 million.
  - Period: first quarter 2026
  - Revenue: $43 million
  - Result: reported results
  source text: CASGEVY generated first quarter 2026 revenue of $43 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/0001193125-26-204147-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.